Host proteins involved in HIV infection: New therapeutic targets

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 3, 2010, Pages 313-321

  Arhel, Nathalie ^a   Kirchhoff, Frank ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Antiviral restrictions; HIV; Protein protein interactions; Therapy

Indexed keywords

AMPHOTERICIN B METHYL ESTER; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; GLYCOPROTEIN GP 120; IBALIZUMAB; MARAVIROC; NEF PROTEIN; PLERIXAFOR; PROTEIN; RANTES; RECOMBINANT ALPHA INTERFERON; REV PROTEIN; SMALL INTERFERING RNA; TETHERIN; TRANSACTIVATOR PROTEIN; TRIPARTITE MOTIF PROTEIN 5; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS RECEPTOR; VPU PROTEIN;

CD4+ T LYMPHOCYTE; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; VIRUS INTEGRATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 74849097080     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.12.003     Document Type: Review

References (128)

1. De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev. Med. Virol. 19 (2009) 287-299
2. Fauci A.S. 25 years of HIV/AIDS science: reaching the poor with research advances. Cell 131 (2007) 429-432
3. Quinn T.C. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 22 (2008) S7-S12
4. Mascolini M., Richman D., Larder B., Mellors J., and Boucher C.A. Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations. Antivir. Ther. 13 (2008) 319-334
5. Grunfeld C. Understanding the complications of antiretroviral drugs. Clin. Infect. Dis. 47 (2008) 575-576
6. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., and Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
7. Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., and Elledge S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 (2008) 921-926 Feb
8. König R., Zhou Y., Elleder D., Diamond T.L., Bonamy G.M., Irelan J.T., Chiang C.Y., Tu B.P., De Jesus P.D., Lilley C.E., Seidel S., Opaluch A.M., Caldwell J.S., Weitzman M.D., Kuhen K.L., Bandyopadhyay S., Ideker T., Orth A.P., Miraglia L.J., Bushman F.D., Young J.A., and Chanda S.K. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135 (2008) 49-60
9. Zhou H., Xu M., Huang Q., Gates A.T., Zhang X.D., Castle J.C., Stec E., Ferrer M., Strulovici B., Hazuda D.J., and Espeseth A.S. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4 (2008) 495-504
10. Malim M.H., and Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3 (2008) 388-398
11. Neil S., and Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res. 29 (2009) 569-580
12. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 (2004) 848-853
13. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
14. Neil S.J., Zang T., and Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 (2008) 425-430
15. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., and Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3 (2008) 245-252
16. Bannert N., and Kurth R. Retroelements and the human genome: new perspectives on an old relation. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14572-14579
17. Sattentau Q.J., and Weiss R.A. The CD4 antigen: physiological ligand and HIV receptor. Cell 52 (1988) 631-633
18. J.C. Tilton, R.W. Doms, Entry inhibitors in the treatment of HIV-1 infection, Antiviral Res. (2009) [Electronic publication ahead of print].
19. Kuritzkes D.R., Jacobson J., Powderly W.G., Godofsky E., DeJesus E., Haas F., Reimann K.A., Larson J.L., Yarbough P.O., Curt V., and Shanahan Jr. W.R. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189 (2004) 286-291
20. Zhang Z.Q., Sorensen M., Fung M., and Schooley R.T. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob. Agents Chemother. 50 (2006) 2231-2233
21. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC-CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
22. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., and Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (1996) 1135-1148
23. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
24. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Collman R.G., and Doms R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996) 1149-1158
25. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., Schwartz O., Heard J.M., Clark-Lewis I., Legler D.F., Loetscher M., Baggiolini M., and Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382 (1996) 833-835
26. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., and Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
27. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cogniaux J., Forceille C., Muyldermans G., Verhofsted C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collmam R.G., Doms R.W., Vassart G., and Parmentier M. Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 382 (1996) 722-725
28. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., and O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996) 1856-1862
29. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., Kang S., Ceradini D., Jin Z., Yazdanbakhsh K., Kunstman K., Erickson D., Dragon E., Landau N.R., Phair J., Ho D.D., and Koup R.A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2 (1996) 1240-1243
30. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., Buser R., Wells T.N., and Proudfoot A.E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276 (1997) 276-279
31. Mosier D.E., Picchio G.R., Gulizia R.J., Sabbe R., Poignard P., Picard L., Offord R.E., Thompson D.A., and Wilken J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73 (1999) 3544-3550
32. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., Piatak Jr. M., Lifson J.D., Salkowitz J.R., Rodriguez B., Blauvelt A., and Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306 (2004) 485-487
33. Gaertner H., Cerini F., Escola J.M., Kuenzi G., Melotti A., Offord R., Rossitto-Borlat I., Nedellec R., Salkowitz J., Gorochov G., Mosier D., and Hartley O. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 17706-17711
34. Sayana S., and Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev. Anti Infect. Ther. 7 (2009) 9-19
35. Esté J.A., and Telenti A. HIV entry inhibitors. Lancet 370 (2007) 81-88
36. Klibanov O.M. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 10 (2009) 845-859
37. Anderson J., and Akkina R. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther. 14 (2007) 1287-1297
38. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., Yao J., Haridas V., Habiro K., Yang Y.G., Jeong J.H., Lee K.Y., Kim Y.H., Kim S.W., Peipp M., Fey G.H., Manjunath N., Shultz L.D., Lee S.K., and Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134 (2008) 577-586
39. Hütter G., Nowak D., Mossner M., Ganepola S., Müssig A., Allers K., Schneider T., Hofmann J., Kücherer C., Blau O., Blau I.W., Hofmann W.K., and Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 (2009) 692-698
40. Jensen M.A., Coetzer M., van 't Wout A.B., Morris L., and Mullins J.I. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J. Virol. 80 (2006) 4698-4704
41. Hütter G., Schneider T., and Thiel E. Transplantation of selected or transgenic blood stem cells-a future treatment for HIV/AIDS?. J. Int. AIDS Soc. 12 (2009) 10
42. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr. Opin. HIV AIDS 4 (2009) 131-135
43. C.S. Adamson, E.O. Freed, Novel approaches to inhibiting HIV-1 replication, Antiviral Res. (2009) [Electronic publication ahead of print].
44. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., and Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393 (1998) 591-594
45. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., and Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393 (1998) 595-599
46. Wong D., and Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin. Cancer Res. 14 (2008) 7975-7980
47. Müller B., and Kräusslich H.G. Antiviral strategies. Handb. Exp. Pharmacol. 189 (2009) 1-24
48. Emerman M., and Malim M.H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280 (1998) 1880-1884
49. Zhou Q., and Yik J.H. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev. 70 (2006) 646-659
50. Bieniasz P.D., Grdina T.A., Bogerd H.P., and Cullen B.R. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7791-7796
51. Richter S.N., and Palù G. Inhibitors of HIV-1 Tat-mediated transactivation. Curr. Med. Chem. 13 (2006) 1305-1315
52. Harrich D., McMillan N., Munoz L., Apolloni A., and Meredith L. Will diverse Tat interactions lead to novel antiretroviral drug targets?. Curr. Drug Targets 7 (2006) 1595-1606
53. Chao S.H., and Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276 (2001) 31793-31799
54. Pollard V.W., and Malim M.H. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52 (1998) 491-532
55. Hope T.J. The ins and outs of HIV. Rev. Arch. Biochem. Biophys. 365 (1999) 186-191
56. Dayton A.I. Within you, without you: HIV-1 Rev and RNA export. Retrovirology 1 (2004) 35
57. Yedavalli V.S., Neuveut C., Chi Y.H., Kleiman L., and Jeang K.T. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119 (2004) 381-392
58. Ishaq M., Hu J., Wu X., Fu Q., Yang Y., Liu Q., and Guo D. Knockdown of cellular RNA helicase DDX3 by short hairpin RNAs suppresses HIV-1 viral replication without inducing apoptosis. Mol. Biotechnol. 39 (2008) 231-238
59. Rossi J.J., June C.H., and Kohn D.B. Genetic therapies against HIV. Nat. Biotechnol 25 (2007) 1444-1454
60. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., De Clercq E., and Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278 (2003) 372-381
61. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., Teo W., and Poeschla E.M. An essential role for LEDGF/p75 in HIV integration. Science 314 (2006) 461-464
62. Emiliani S., Mousnier A., Busschots K., Maroun M., Van Maele B., Tempé D., Vandekerckhove L., Moisant F., Ben-Slama L., Witvrouw M., Christ F., Rain J.C., Dargemont C., Debyser Z., and Benarous R. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J. Biol. Chem. 280 (2005) 25517-25523
63. Cherepanov P., Sun Z.Y., Rahman S., Maertens G., Wagner G., and Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat. Struct. Mol. Biol. 12 (2005) 526-532
64. Hare S., Shun M.C., Gupta S.S., Valkov E., Engelman A., and Cherepanov P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog. 5 (2009) 259
65. Engelman A., and Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 4 (2008) 46
66. von Schwedler U.K., Stuchell M., Muller B., Ward D.M., Chung H.Y., Morita E., Wang H.E., Davis T., He G.P., Cimbora D.M., Scott A., Kräusslich H.G., Kaplan J., Morham S.G., and Sundquist W.I. The Protein Network of HIV Budding. Cell 114 (2003) 701-713
67. Martin-Serrano J., Zang T., and Bieniasz P.D. Role of ESCRT-I in retroviral budding. J. Virol. 77 (2003) 4794-4804
68. Stuchell M.D., Garrus J.E., Muller B., Stray K.M., Ghaffarian S., McKinnon R., Kräusslich H.G., Morham S.G., and Sundquist W.I. The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J. Biol. Chem. 279 (2004) 36059-36071
69. Garrus J.E., von Schwedler U.K., Pornillos O.W., Morham S.G., Zavitz K.H., Wang H.E., Wettstein D.A., Stray K.M., Cote M., Rich R.L., Myszka D.G., and Sundquist W.I. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107 (2001) 55-65
70. Martin-Serrano J., Zang T., and Bieniasz P.D. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7 (2001) 1313-1319
71. VerPlank L., Bouamr F., LaGrassa T.J., Agresta B., Kikonyogo A., Leis J., and Carter C.A. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7724-7729
72. Tavassoli A., Lu Q., Gam J., Pan H., Benkovic S.J., and Cohen S.N. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. A. C. S. Chem. Biol. 3 (2008) 757-764
73. Strack B., Calistri A., Craig S., Popova E., and Göttlinger H.G. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114 (2003) 689-699
74. Fujii K., Hurley J.H., and Freed E.O. Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1. Nat. Rev., Microbiol. 5 (2007) 912-916
75. Fellay J., Shianna K.V., Ge D., Colombo S., Ledergerber B., Weale M., Zhang K., Gumbs C., Castagna A., Cossarizza A., Cozzi-Lepri A., De Luca A., Easterbrook P., Francioli P., Mallal S., Martinez-Picado J., Miro J.M., Obel N., Smith J.P., Wyniger J., Descombes P., Antonarakis S.E., Letvin N.L., McMichael A.J., Haynes B.F., Telenti A., and Goldstein D.B. A whole-genome association study of major determinants for host control of HIV-1. Science 317 (2007) 944-947
76. Fu W., Sanders-Beer B.E., Katz K.S., Maglott D.R., Pruitt K.D., and Ptak R.G. Human immunodeficiency virus type 1, human protein interaction database at NCBI. Nucleic Acids Res. 37 (2009) D417-422
77. Ptak R.G., Fu W., Sanders-Beer B.E., Dickerson J.E., Pinney J.W., Robertson D.L., Rozanov M.N., Katz K.S., Maglott D.R., Pruitt K.D., and Dieffenbach C.W. Cataloguing the HIV-1 human protein interaction network, AIDS Res. Hum. Retrovir. 24 (2008) 1497-1502
78. Pinney J.W., Dickerson J.E., Fu W., Sanders-Beer B.E., Ptak R.G., and Robertson D.L. HIV-host interactions: a map of viral perturbation of the host system. AIDS 23 (2009) 549-554
79. Bushman F.D., Malani N., Fernandes J., D'Orso I., Cagney G., Diamond T.L., Zhou H., Hazuda D.J., Espeseth A.S., König R., Bandyopadhyay S., Ideker T., Goff S.P., Krogan N.J., Frankel A.D., Young J.A., and Chanda S.K. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 5 (2009) 437
80. Nguyen D.G., Wolff K.C., Yin H., Caldwell J.S., and Kuhen K.L. "UnPAKing" human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol. 80 (2006) 130-137
81. Yeung M.L., Houzet L., Yedavalli V.S., and Jeang K.T. A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J. Biol. Chem. 284 (2009) 19463-19473
82. Henriet S., Mercenne G., Bernacchi S., Paillart J.C., and Marquet R. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev. 73 (2009) 211-232
83. Goila-Gaur R., and Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5 (2008) 51
84. Nisole S., Stoye J.P., and Saïb A. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev., Microbiol. 3 (2005) 799-808
85. Towers G.J. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4 (2007) 40
86. Sawyer S.L., Emerman M., and Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2 (2004) 275
87. Sawyer S.L., Wu L.I., Emerman M., and Malik H.S. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2832-2837
88. McNatt N.W., Zang T., Hatziioannou T., Bartlett M., Fofana I.B., Johnsonm W.E., Neil S.J., and Bieniasz P.D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5 (2009) 300
89. Song B., Gold B., O'Huigin C., Javanbakht H., Li X., Stremlau M., Winkler C., Dean M., and Sodroski J. The B302(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. J. Virol. 79 (2005) 6111-6121
90. Esnault C., Heidmann O., Delebecque F., Dewannieux M., Ribet D., Hance A.J., Heidmann T., and Schwartz O. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433 (2005) 430-433
91. Chiu Y.L., and Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26 (2008) 317-353
92. Land A.M., Ball T.B., Luo M., Pilon R., Sandstrom P., Embree J.E., Wachihi C., Kimani J., and Plummer F.A. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82 (2008) 8172-8182
93. Piantadosi A., Humes D., Chohan B., McClelland R.S., and Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J. Virol. 83 (2009) 7805-7814
94. Ulenga N.K., Sarr A.D., Hamel D., Sankale J.L., Mboup S., and Kanki P.J. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res. Hum. Retrovir. 24 (2008) 1285-1290
95. Nathans R., Cao H., Sharova N., Ali A., Sharkey M., Stranska R., Stevenson M., and Rana T.M. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26 (2008) 1187-1192
96. Harris R.S. Enhancing immunity to HIV through APOBEC. Nat. Biotechnol. 26 (2008) 1089-1090
97. Chen K., Huang J., Zhang C., Huang S., Nunnari G., Wang F.X., Tong X., Gao L., Nikisher K., and Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 80 (2006) 7645-7657
98. Peng G., Lei K.J., Jin W., Greenwell-Wild T., and Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203 (2006) 41-46
99. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., and Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5514-5519
100. Sebastian S., and Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2 (2005) 40
101. Anderson J., and Akkina R. Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum. Gene Ther. 19 3 (2008 Mar) 217-228
102. Neagu M.R., Ziegler P., Pertel T., Strambio-De-Castillia C., Grütter C., Martinetti G., Mazzucchelli L., Grütter M., Manz M.G., and Luban J. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119 (2009) 3035-3047
103. Carthagena L., Bergamaschi A., Luna J.M., David A., Uchil P.D., Margottin-Goguet F., Mothes W., Hazan U., Transy C., Pancino G., and Nisole S. Human TRIM gene expression in response to interferons. PLoS One 4 (2009) 4894
104. Uchil P.D., Quinlan B.P., Chan W.T., Luna J.M., and Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4 (2008) 16
105. D. Sauter, M. Schindler, A. Specht, W.N. Landford, J. Münch, K.A. Kim, J. Votteler, U. Schubert, F. Bibollet-Ruche, B.F. Keele, J. Takehisa, Y. Ogando, C. Ochsenbauer, J.C. Kappes, A. Ajouba, M. Peeters, G.H. Learn, G. Shaw, P.M. Sharp, P. Bieniasz, B.H. Hahn, T. Hatziioannou, F. Kirchhoff, The evolution of pandemic and non-pandemic HIV-1 strains has been driven by Tetherin antagonism, Cell Host Microbe 6 (2009) 409-421.
106. Jia B., Serra-Moreno R., Neidermyer W., Rahmberg A., Mackey J., Fofana I.B., Johnson W.E., Westmoreland S., and Evans D.T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5 (2009) 429
107. Zhang F., Wilson S.J., Landford W.C., Virgen B., Gregory D., Johnson M.C., Munch J., Kirchhoff F., Bieniasz P.D., and Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6 (2009) 54-67
108. A. Le Tortorec A, S.J. Neil, Antagonism and intracellular sequestration of human tetherin by the HIV-2 envelope glycoprotein, J Virol. 83 (2009) 11966-11978.
109. Kaletsky R.L., Francica J.R., Agrawal-Gamse C., and Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 2886-2891
110. Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y., McNatt M., Hatziioannou T., and Bieniasz P.D. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83 (2009) 1837-1844
111. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Kräusslich H.G., Fackler O.T., and Keppler O.T. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5 (2009) 285-297
112. Mangeat B., Gers-Huber G., Lehmann M., Zufferey M., Luban J., and Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5 (2009) 574
113. Kawai S., Azuma Y., Fujii E., Furugaki K., Ozaki S., Matsumoto T., Kosaka M., and Yamada-Okabe H. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 99 (2008) 2461-2466
114. Lane H.C., Kovacs J.A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J.A., Baseler M., and Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 2 (1988) 1218-1222
115. Stacey A.R., Norris P.J., Qin L., Haygreen E.A., Taylor E., Heitman J., Lebedeva M., DeCamp A., Li D., Grove D., Self S.G., and Borrow P. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83 (2009) 3719-3733
116. Hosmalin A., and Lebon P. Type I IFN interferon production in HIV-infected patients. J. Leukoc. Biol. 80 (2006) 984-993
117. Waheed A.A., Ablan S.D., Mankowski M.K., Cummins J.E., Ptak R.G., Schaffner C.P., and Freed E.O. Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J. Biol. Chem. 281 (2006) 28699-28711
118. Waheed A.A., Ablan S.D., Soheilian F., Nagashima K., Ono A., Schaffner C.P., and Freed E.O. Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. J. Virol. 82 (2008) 9776-9781
119. Hrecka K., Gierszewska M., Srivastava S., Kozaczkiewicz L., Swanson S.K., Florens L., Washburn M.P., and Skowronski J. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11778-11783
120. Le Rouzic E., Belaïdouni N., Estrabaud E., Morel M., Rain J.C., Transy C., and Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6 (2007) 182-188
121. Schröfelbauer B., Hakata Y., and Landau N.R. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 4130-4135
122. Goujon C., Rivière L., Jarrosson-Wuilleme L., Bernaud J., Rigal D., Darlix J.L., and Cimarelli A. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 4 (2007) 2
123. Sharova N., Wu Y., Zhu X., Stranska R., Kaushik R., Sharkey M., and Stevenson M. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog. 4 (2008) 57
124. Kirchhoff F., Schindler M., Specht A., Arhel N., and Münch J. Role of Nef in primate lentiviral immunopathogenesis. Cell. Mol. Life Sci. 65 (2008) 2621-3636
125. N. Arhel, F. Kirchhoff, Implications of Nef: Host cell interactions in viral persistence and progression to AIDS, Curr. Top. Microbiol. Immunol. 339 (2010) 147-175.
126. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev., Drug Discov. 1 (2002) 727-730
127. Sodora D.L., Allan J.S., Apetrei C., Brenchley J.M., Douek D.C., Else J.G., Estes J.D., Hahn B.H., Hirsch V.M., Kaur A., Kirchhoff F., Muller-Trutwin M., Pandrea I., Schmitz J.E., and Silvestri G. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat. Med. 15 (2009) 861-865
128. Paiardini M., Pandrea I., Apetrei C., and Silvestri G. Lessons learned from the natural hosts of HIV-related viruses. Annu. Rev. Med. 60 (2009) 485-495